Carbometrics

Carbometrics is a private, pre-revenue biotech spin-out from the University of Bristol, leveraging foundational intellectual property from the acquisition of Ziylo by Novo Nordisk. Its core asset is a proprietary synthetic Glucose Binding Molecule (GBM), published in Nature Chemistry, which offers exceptional selectivity, stability, and signal-coupling versatility for glucose sensing. The company is focused on partnering its GBM platform to enhance the performance of CGM devices, targeting improved accuracy, longevity, and reduced interference in the rapidly expanding digital health and diabetes management markets.

Proprietary synthetic Glucose Binding Molecules (GBMs): biomimetic, highly selective, and stable synthetic receptors for glucose enabling versatile signal coupling for continuous monitoring applications.

Carbometrics competes with dominant CGM companies (Dexcom, Abbott) that use glucose oxidase enzyme-based sensors, and with other firms developing next-gen sensing tech like other synthetic receptors or non-enzymatic methods. Its primary competitive edge is the peer-validated, biomimetic design of its GBM, which combines high selectivity and exceptional stability—a combination not yet achieved by commercial alternatives.